GBS NN
Alternative Names: GBS NN/NN2; GBS vaccine - Minervax; GBS-NN/NN2 vaccine; Group B Streptococcal vaccine - Minervax; Streptococcal B vaccine - MinervaxLatest Information Update: 18 Jul 2024
At a glance
- Originator Lund University
- Developer Minervax
- Class Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Streptococcal infections
Most Recent Events
- 10 Jul 2024 Minervax ApS plans to initiate a phase II/III trial for Streptococcus Agalactiae Infection (In volunteers) in 2024 (IM) (NCT06494475)
- 23 May 2024 Minervax completes a phase I trial in Streptococcal infections (Prevention, In the elderly) in Belgium (IM) (NCT05782179)
- 18 Oct 2023 MinervaX completes a phase II trial in Streptococcal infections (In infants, In adults, In neonates, Prevention) in Denmark, South Africa and United Kingdom (IM) (NCT05154578)